Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge

Trial Profile

A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2019

At a glance

  • Drugs ZED 1227 (Primary)
  • Indications Coeliac disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Dr Falk Pharma
  • Most Recent Events

    • 26 Apr 2018 The study design was co-developed by Dr. Falk Pharma GmbH and the European experts and clinicians in celiac disease, Prof. Schuppan (Germany), Prof. Markku Maki (Finland), and Prof. Knut Lundin (Norway), as repoted in a Zedira GmbH media release.
    • 14 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top